07.07.14
Oxford, United Kingdom-based Oxford Immunotec Global plc has named Louis O’Dea, MB, BCh, BAO, its new chief medical officer. O’Dea will be supporting the diagnostics technology company with growing its T-spot.TB (tuberculosis) business, and the development of new products through management of Oxford Immunotec’s medical education and clinical trial programs. The T-spot.TB test is used to test for latent tuberculosis infection.
O’Dea brings to Oxford Immunotec more than 20 years of worldwide pharmaceutical, medical device, and biotechnology industry management experience. Prior to joining Oxford Immunotec, O’Dea served as the chief medical officer and head of regulatory affairs at Moderna Therapeutics. Prior to Moderna, he was chief medical officer of Radius Health Inc. and head of clinical development for the Metabolic and Reproductive Health unit of Serono, a division of Merck.
“Oxford Immunotec is a leader in the world of immunology-based diagnostics, proven by the global success of the T-SPOT.TB test and a robust pipeline of products based on its core T-spot technology platform,” said O’Dea. “I look forward to contributing to the company’s continued success as it grows and expands into new markets.”
“Dr. O’Dea is accomplished in successfully managing both pharmaceuticals and devices through clinical trials, regulatory approval and commercialization in the United States, Europe and Japan. We are extremely fortunate to have him join our team,” said CEO Peter Wrighton-Smith, Ph.D. “The breadth and depth of Louis’s clinical development experience will be instrumental to Oxford Immunotec’s efforts to launch new products well-supported with clinical data and well-suited to the needs of the market.”
O’Dea is a board-certified physician in internal medicine and endocrinology in the United States and Canada. He received his MB, BCh, and BAO degrees from University College in Dublin, Ireland, followed by postgraduate training in internal medicine and endocrinology at McGill University (Canada) and a research and clinical fellowship in reproductive endocrinology at Massachusetts General Hospital.
Oxford Immunotec’s U.S. offices are located in Marlborough, Mass. The company develops immunology tests.
O’Dea brings to Oxford Immunotec more than 20 years of worldwide pharmaceutical, medical device, and biotechnology industry management experience. Prior to joining Oxford Immunotec, O’Dea served as the chief medical officer and head of regulatory affairs at Moderna Therapeutics. Prior to Moderna, he was chief medical officer of Radius Health Inc. and head of clinical development for the Metabolic and Reproductive Health unit of Serono, a division of Merck.
“Oxford Immunotec is a leader in the world of immunology-based diagnostics, proven by the global success of the T-SPOT.TB test and a robust pipeline of products based on its core T-spot technology platform,” said O’Dea. “I look forward to contributing to the company’s continued success as it grows and expands into new markets.”
“Dr. O’Dea is accomplished in successfully managing both pharmaceuticals and devices through clinical trials, regulatory approval and commercialization in the United States, Europe and Japan. We are extremely fortunate to have him join our team,” said CEO Peter Wrighton-Smith, Ph.D. “The breadth and depth of Louis’s clinical development experience will be instrumental to Oxford Immunotec’s efforts to launch new products well-supported with clinical data and well-suited to the needs of the market.”
O’Dea is a board-certified physician in internal medicine and endocrinology in the United States and Canada. He received his MB, BCh, and BAO degrees from University College in Dublin, Ireland, followed by postgraduate training in internal medicine and endocrinology at McGill University (Canada) and a research and clinical fellowship in reproductive endocrinology at Massachusetts General Hospital.
Oxford Immunotec’s U.S. offices are located in Marlborough, Mass. The company develops immunology tests.